Royalty Pharma IPO: is the stock worth the hype?
Jun 19, 2020 · Royalty Pharma managed $10bn in assets by 2013, a figure that grew to $16bn by 2019. According to the company’s financial reports, Royalty Pharma’s net income rose from $581m in 2015 to $2.35bn in 2019. In the first quarter of 2020, the firm’s revenue surged 15 per cent year-on-year to a whopping $500.9m. Royalty Pharma IPO details
DA: 27 PA: 4 MOZ Rank: 80